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Variable Min Max
Symptomatic patients who had CAS (vs CEA), % 7 32
Asymptomatic patients who had
CAS (vs CEA), %
7 23
CEA with symptoms, % 20 42
CAS with symptoms, % 10 53
CEA with patch, % 73 95
CEA with shunt use, % 33 76
CEA where EEG used by surgeons who
routinely shunt, %
0 68
CAS on both antiplatelet and statin, % 60 82
CAS discharged on both antiplatelet and statin, % 75 91
Asymptomatic CAS with stenosis >70%, % 67 97
CAS predialated, % 27 68
CAS postdialated, % 60 96
All P < .01.PS116.
Are NASCET and ACAS Guidelines Applicable to
Modern Imaging Measurements: Digital Subtraction
Angiography vs TeraRecon CTA
Ashley Aaron, Adithya Suresh, Steven Santilli, Rumi Faizer,
Steven Levin. University of Minnesota, St. Paul, Minn
Objectives: The North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET) and Asymptomatic
Carotid Artery Surgery Trial, helped establish guidelines
for carotid intervention based on conventional angiography
measurements of stenosis. However, with improvement in
noninvasive imaging techniques, the use of computed to-
mography angiography (CTA) has become widespread.
The goal of this retrospective evaluation was to compare
the degree of carotid stenosis based on TeraRecon
compared with angiography and how these potential differ-
ences may impact decisions for intervention.
Methods: The percentage of carotid stenosis was ob-
tained via digital subtraction angiography and TeraRecon.
The study population included 58 patients who underwent
carotid artery stenting for symptomatic and asymptomatic ca-
rotid stenosis between 2006 and 2013. The TeraRecon CTA
and angiography stenosis measurements were analyzed by
Student t-test to determine if traditional NASCET angiog-
raphy determinations for intervention are applicable to CTA.
Results: TeraRecon CTA measurements of the per-
centage of carotid artery stenosis were, on average, 6.5%
higher than those based on angiography. Analysis with
the Student t-test showed a statistically signiﬁcant differ-
ence between the two measurements (P ¼ .0033).
Conclusions: Overall, we found that measurements of
percent carotid artery stenosis in asymptomatic and symp-
tomatic patients undergoing carotid stent placement were
higher when using TeraRecon CTA compared with mea-
sures with angiography. This prompts the question have
we been over-intervening on patients by using NASCET
and ACAS guidelines on patients imaged with CTA?
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Regional Differences in Patient Selection and
Treatment of Carotid Artery Disease in the Society
for Vascular Surgery Vascular Quality Initiative (SVS
VQI)
John C. McCallum1, Thomas Curran1, Dominique B.
Buck1, Jeremy D. Darling1, Joe Schneider3, Brian W.
Nolan2, Philip P. Goodney2, Marc L. Schermerhorn1.
1Vascular Surgery, Beth Israel Deaconess Medical Center,
Boston, Mass; 2Dartmouth Hitchcock Medical Center,
Hanover, NH; 3Northwestern University Feinberg
School of Medicine, Chicago, IllObjectives: There are limited data on the regional
variation of carotid endarterectomy (CEA) and carotid
stenting (CAS). We use the Society for Vascular Surgery
Vascular Quality Initiative (SVS-VQI) to evaluate regional
differences in CEA and CAS across the United States.
Methods: We used the SVS-VQI to identify pa-
tients undergoing CEA and CAS between 2009 and
2012. Each of 14 regions was evaluated. Regions per-
forming <50 CAS were excluded, leaving nine regions.
Results: A total of 14,871 cases were performed, and a
minority of cases used CAS (vs CEA) to treat both symptom-
atic and asymptomatic disease. Substantial regional variation in
patient characteristics (eg, symptom status, stenosis >70%),
technical approach (eg, CEA vs stent, patch use, shunt use,
neurologic monitoring, cerebral protection device use and
type), and evidence-based process measures (eg, antiplatelet
and statin use, patch use) are demonstrated in the Table.
Conclusions: This ﬁrst investigation of a national clin-
ical database demonstrates signiﬁcant regional variation in
carotid disease management. Future studies on the associ-
ation of regional variation with risk-adjusted outcomes
offer the opportunity for quality improvement through
prospective identiﬁcation of best practices.Author Disclosures: D. B. Buck: Nothing to disclose; T.
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Outcomes After Early and Delayed Carotid
Endarterectomy in Patients With Symptomatic
Carotid Artery Stenosis
Ying Huang, Peter Gloviczki, Audra A. Duncan, Manju
Kalra, Gustavo S. Oderich, Mark D. Fleming, Randall R.
De Martino, Thomas C. Bower. Division of Vascular and
Endovascular Surgery, Mayo Clinic, Rochester, Minn
Objectives: To deﬁne outcomes after carotid endar-
terectomy (CEA) in symptomatic patients when operated
on #14 days after onset of symptoms or later (<14 days).
Methods: Clinical data of consecutive patients who
underwent CEA (2003-2012) for symptomatic carotid
Table. Outcomes after CEA
Variable
30-day 5-year
Overall (n¼ 231) Group 1 (n ¼ 58) Group 2 (n ¼ 173)
P
Overall Group 1 Group 2
PNo. (%) No. (%) No. (%) (%) (%) (%)
Stroke + death 6 (2.6) 4 (6.9) 2 (1.2) .29 24 37 20 .07
Death 1 (0.4) 0 (0) 1 (0.6) .81 20 29 18 .57
Stroke 5 (2.2) 4 (6.9) 1 (0.6) .07 7.0 11 5.5 .03
MI 4 (1.7) 0 (0) 4 (2.3) .24 1.8 0 2.4 .24
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toms (minor stroke, transient ischemic attack, TIA)
occurred #14 days; and in group 2 symptoms occurred
>14 days before CEA. Primary end points were com-
bined stroke and death; secondary end points were
stroke, death, and myocardial infarction (MI).
Results: A total of 231 CEAs were performed in 226
symptomatic patients (32% female; mean age, 72 6 8.7
years), comprising 58 (25%) in group 1 and 173 (75%) in
group 2. Sixty patients (26%) presented with stroke
(group1, 19%; group 2, 28%; P ¼ .16). The 30-day stroke
and death rate was 2.6% and not signiﬁcantly different be-
tween groups (Table). Three of four early strokes in group
1 occurred in patients with repeated transient ischemic at-
tacks #2 days before CEA. Mean follow-up was 3.9 years
(range, 30 days-10.8 years). The Table presents 5-year out-
comes. In multivariable analysis, patients with symptoms
#14 days tended to have increased rate of stroke.
Conclusions: CEA can be performed in symptomatic
patients with a 30-day stroke and death rate of 2.6%, but
there was a trend to increased rate of stroke if the opera-
tion was performed #14 days after onset of symptoms. Pa-
tients with repeated transient ischemic attacks, operated
on #2 days, had the highest risk of stroke. For this select
group of symptomatic patients, outcomes quoted based on
prospective randomized trials may not apply.
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Risk Factors for Suboptimal Medical Therapy in
Patients Undergoing Revascularization for
Symptomatic Peripheral Arterial Disease: A Vascular
Study Group of Greater New York Initiative
Andrew J. Meltzer, Art Sedrakyan, Abby Isaacs, Ellen C.
Meltzer, Peter H. Connolly, Darren B. Schneider. Vascular
Surgery, Weill Cornell Medical College, New York, NY
Objectives: The objective of this study is to identify
risk factors for suboptimal medical therapy among patients
undergoing surgical bypass and percutaneous interventions
for symptomatic peripheral arterial disease (PAD).Methods: The Vascular Study Group of Greater
New York (VSGGNY) database was used to identify all
patients undergoing percutaneous therapy or surgical
bypass for PAD (2011-2013). Bivariate analyses were
performed to identify factors associated with preoperative
statin use and antiplatelet therapy. Multivariate relative
risk regression models were developed to identify pa-
tients at risk for suboptimal medical therapy.
Results: A total of 1030 patients underwent endo-
vascular therapy (n ¼ 822 [80%]) or surgical bypass
(n ¼ 208 [20%]) for symptomatic peripheral arterial dis-
ease (57.2% claudication, 15% rest pain, 27.8% tissue
loss). Preoperative statin use was observed in 59%. An-
tiplatelet therapy was observed in 79% of patients.
Bivariate analysis revealed reduced statin use among pa-
tients without other cardiovascular risk factors such as
hypertension (63% vs 39.3%; P < .0001) and coronary
artery disease (CAD) with prior cardiac revasculariza-
tion (coronary artery bypass grafting [CABG]/percuta-
neous coronary intervention [PCI]; 75.2% vs 47.4%; P
< .0001). Multivariate relative risk regression conﬁrmed
increased statin use among patients with other cardio-
vascular risk factors including hypertension (1.14
[1.02-1.27]; P ¼ .02), and CAD with prior CABG/
PCI (1.22 [1.13-1.31]; P < .0001). There was a clear
trend towards reduced statin use in patients aged >80
(0.92 [0.84-0.1.0]; P ¼ .059). By multivariate regres-
sion, antiplatelet therapy use was associated with CAD
and prior CABG/PCI (1.11 [1.04-1.17]; P ¼ .0015)
and prior peripheral revascularization (1.07 [1.01-
1.13]; P ¼ .03).
Conclusions: Patients with symptomatic PAD, but
without an antecedent cardiovascular history, are less likely
to be optimally managed with statins and antiplatelet ther-
apy preoperatively and should be actively targeted for med-
ical optimization by vascular specialists.
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